Home » Author Archive

CRISPR Therapeutics (NASDAQ:CRSP) Given New $56.00 Price Target at Barclays

Posted by John Adams on Feb 13th, 2025

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective raised by Barclays from $55.00 to $56.00 in a report published on Wednesday morning,Benzinga reports. Barclays currently has an equal weight rating on the... More of this article »

Barclays Has Lowered Expectations for Fluence Energy (NASDAQ:FLNC) Stock Price

Posted by John Adams on Feb 13th, 2025

Fluence Energy (NASDAQ:FLNC – Free Report) had its target price reduced by Barclays from $22.00 to $9.00 in a research note released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock. A... More of this article »

HMS Capital Management LLC Makes New $262,000 Investment in Global X Future Analytics Tech ETF (NASDAQ:AIQ)

Posted by John Adams on Feb 13th, 2025

HMS Capital Management LLC acquired a new position in Global X Future Analytics Tech ETF (NASDAQ:AIQ – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The... More of this article »

5,087 Shares in ANSYS, Inc. (NASDAQ:ANSS) Purchased by Phraction Management LLC

Posted by John Adams on Feb 13th, 2025

Phraction Management LLC bought a new position in shares of ANSYS, Inc. (NASDAQ:ANSS – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm bought 5,087 shares of the software maker’s stock, valued at... More of this article »

Marks Group Wealth Management Inc Sells 15,178 Shares of Manulife Financial Co. (NYSE:MFC)

Posted by John Adams on Feb 13th, 2025

Marks Group Wealth Management Inc lowered its holdings in shares of Manulife Financial Co. (NYSE:MFC – Free Report) (TSE:MFC) by 50.7% in the fourth quarter, HoldingsChannel reports. The firm owned 14,759 shares of the financial... More of this article »